'Toulouse-Lautrec Disease' | Cathepsin K Deficiency | Dense Fragile Bones
- Cathepsin K deficiency - CTSK gene mutation causing defective osteoclast bone resorption (collagen degradation impaired)
- Dense but fragile bones - osteosclerosis paradoxically associated with increased fracture risk and delayed healing
- Acroosteolysis - pathognomonic resorption of distal phalanges (terminal tufts) distinguishes from osteopetrosis
- Open fontanelles - persistent wide-open fontanelles and sutures throughout life (cranial sutures fail to close)
- Toulouse-Lautrec - famous French artist Henri de Toulouse-Lautrec is believed to have had this condition
- “Distinguish from osteopetrosis: pyknodysostosis has acroosteolysis (osteopetrosis does not)
- “Bisphosphonates are contraindicated - bone resorption is already deficient; further inhibition worsens pathology
- “Mandibular osteomyelitis is a characteristic complication due to dental extraction and poor bone vascularity
- “Know the clinical triad: short stature, osteosclerosis, acroosteolysis
CTSK gene mutation causes defective osteoclast function - specifically impaired collagen type I degradation. Osteoclasts can demineralize bone but cannot degrade the organic matrix. This leads to accumulation of undigested collagen in resorption lacunae. Inheritance is autosomal recessive.
Osteosclerosis with fragility - despite increased radiographic density, bones fracture easily. The abnormal bone lacks proper remodeling, leading to accumulation of microdamage. Fractures heal slowly due to impaired bone turnover. Lower limb fractures are most common.
Terminal phalangeal resorption - acroosteolysis of the distal phalanges is pathognomonic and distinguishes pyknodysostosis from osteopetrosis. The mechanism is unclear but may relate to altered mechanical stress or vascular compromise in acral regions.
Do NOT use bisphosphonates - bone resorption is already severely impaired. Further inhibition of osteoclast function with bisphosphonates would worsen the underlying pathology. There is no disease-modifying treatment; management is supportive and symptomatic.
- Key Features
- Diffuse osteosclerosis, short stature
- Management
- Genetic testing, family counseling, surveillance
- Exam Pearl
- Check for acroosteolysis to distinguish from osteopetrosis
- Key Features
- Long bone fractures despite dense bone
- Management
- Standard fixation, prolonged immobilization, patience
- Exam Pearl
- Expect delayed union; avoid early hardware removal
- Key Features
- Osteomyelitis, chronic drainage, pain
- Management
- Debridement, prolonged antibiotics, involve OMFS
- Exam Pearl
- Mandibular osteomyelitis is characteristic complication
DENSEKey Features of Pyknodysostosis
Hook:DENSE bones that are DENSE but FRAGILE - remember pyknodysostosis has DENSE bones with the DENSE mnemonic!
PYKNODistinguishing Features from Osteopetrosis
Hook:PYKNO - Pyknodysostosis has unique features that distinguish it from its cousin osteopetrosis!
Overview and Epidemiology
Pyknodysostosis (from Greek: pyknos = dense, dys = defective, ostosis = bone condition) is a rare autosomal recessive sclerosing bone dysplasia first described by Maroteaux and Lamy in 1962. The condition gained historical interest when it was retrospectively diagnosed in the famous French Post-Impressionist artist Henri de Toulouse-Lautrec (1864-1901), whose short stature and frequent fractures were characteristic. The molecular basis - cathepsin K deficiency - was identified in 1996.
- Incidence: Approximately 1 per 1.7 million births
- Prevalence: Fewer than 200 cases reported worldwide
- Gender: Equal male:female distribution
- Inheritance: Autosomal recessive (consanguinity common)
- Geography: Higher prevalence in populations with consanguinity
- Onset: Present at birth, recognized in childhood
- Progression: Stable bone density, ongoing fracture risk
- Life expectancy: Normal lifespan expected
- Intelligence: Normal cognitive function
- Growth: Progressive short stature, final height less than 150cm
Historical Context
Henri de Toulouse-Lautrec, the renowned French artist known for his vivid depictions of Parisian nightlife, is believed to have had pyknodysostosis. His parents were first cousins (consanguinity), he had short stature (approximately 150cm), and he suffered fractures of both femurs during adolescence from minor trauma. His characteristic facial features and short limbs are consistent with the diagnosis, though this remains retrospective speculation.
Differential Considerations
The key differential diagnosis is osteopetrosis, which also presents with diffuse osteosclerosis. However, pyknodysostosis is distinguished by:
- Acroosteolysis (absent in osteopetrosis)
- Open fontanelles (absent in osteopetrosis)
- Absent paranasal sinuses (may be present in osteopetrosis)
- No bone marrow failure (occurs in severe osteopetrosis)
Pathophysiology and Genetics
Cathepsin K Gene Mutation
Pyknodysostosis is caused by loss-of-function mutations in the CTSK gene (chromosome 1q21) encoding cathepsin K, a lysosomal cysteine protease essential for osteoclast-mediated bone resorption. Cathepsin K is the primary enzyme responsible for degrading type I collagen in the bone matrix. Without functional cathepsin K, osteoclasts can demineralize bone but cannot degrade the organic collagen matrix, leading to accumulation of undigested bone material.
- Gene: CTSK (cathepsin K) on chromosome 1q21
- Protein: Cathepsin K (cysteine protease)
- Mutation type: Loss-of-function, various mutations described
- Expression: Highly expressed in osteoclasts
- Function: Degrades type I collagen in bone matrix
- Osteoclasts: Demineralize but cannot resorb collagen
- Bone matrix: Undigested collagen accumulates
- Remodeling: Severely impaired bone turnover
- Bone quality: Dense but structurally abnormal
- Mechanical properties: Paradoxically brittle
Comparison with Osteopetrosis
While both conditions cause osteosclerosis, the mechanisms differ:
- Cathepsin K deficiency (collagen degradation impaired)
- Demineralization intact, matrix degradation blocked
- Osteoclasts present and partially functional
- Multiple genes (TCIRG1, CLCN7, etc.)
- Complete osteoclast dysfunction or absence
- Both demineralization and matrix degradation impaired
- May have bone marrow failure from medullary cavity obliteration
Histopathology
Microscopic examination of affected bone reveals:
- Normal or increased osteoclast numbers
- Accumulation of demineralized bone matrix in resorption lacunae
- Disorganized bone architecture
- Increased bone mass with abnormal quality
- No evidence of the fibrous tissue seen in fibrous dysplasia
Clinical Features
Cardinal Features
The clinical presentation of pyknodysostosis is characterized by a distinctive combination of features:
- Short stature (adult height typically less than 150cm)
- Craniofacial abnormalities (open fontanelles, obtuse mandibular angle)
- Acroosteolysis (terminal phalangeal resorption)
- Recurrent fractures (despite radiographically dense bones)
- Dental abnormalities (delayed eruption, crowding)
- Open fontanelles: Persist throughout life
- Open cranial sutures: Wormian bones common
- Obtuse mandibular angle: Characteristic profile
- Micrognathia: Small chin, dental crowding
- Frontal bossing: Prominent forehead
- Absence of paranasal sinuses: On imaging
- Short stature: Final height less than 150cm
- Short digits: Brachydactyly with acroosteolysis
- Hypoplastic clavicles: May be dysplastic
- Increased bone density: Generalized osteosclerosis
- Fractures: Common, especially lower limbs
- Delayed healing: Prolonged union times
Physical Examination
- Proportionate short stature (short trunk and limbs)
- Adult height typically 130-150cm
- Normal intelligence and development
- Widely open anterior fontanelle (palpable soft spot)
- Prominent forehead with frontal bossing
- Blue sclerae may be present (not pathognomonic)
- Beaked nose
- Obtuse mandibular angle with relative prognathism
- High-arched palate with dental crowding
- Short, stubby fingers
- Acroosteolysis causes spatulate or drumstick-like terminal phalanges
- Nails may be dystrophic or grooved
- Wrinkled skin over dorsum of hands
- May have kyphoscoliosis
- Joint laxity in some patients
- Muscle mass generally normal
- Gait may be affected by limb deformity
Fracture Patterns
Fractures are a major source of morbidity:
- Location: Lower limbs most common (femur, tibia)
- Mechanism: Minimal trauma sufficient
- Healing: Delayed union is characteristic
- Recurrence: Same bone may fracture multiple times
- Malunion: Deformity common due to repeated fractures
Investigations and Radiographic Features
Diagnostic Imaging
The radiographic appearance of pyknodysostosis is distinctive with three hallmark features: (1) Diffuse osteosclerosis - uniformly increased bone density throughout the skeleton; (2) Acroosteolysis - resorption of terminal phalangeal tufts (pathognomonic); (3) Open fontanelles and sutures - with Wormian bones. The combination of osteosclerosis WITH acroosteolysis is virtually diagnostic.
Regional Findings
Radiographic Features by Region
Widely open fontanelles and sutures with Wormian bones. Obtuse mandibular angle with hypoplastic mandible. Absence or hypoplasia of paranasal sinuses and mastoids. Thickened calvarium with increased density. Frontal bossing apparent on lateral view.
Diffuse sclerosis of vertebrae with no sandwich appearance (unlike osteopetrosis). May have spondylolysis or spondylolisthesis. Posterior elements may be hypoplastic. Cervical vertebral abnormalities may occur.
Generalized osteosclerosis with increased medullary density. Cortices may be thickened. Metaphyseal modeling is relatively preserved (unlike Erlenmeyer flask of osteopetrosis). Previous fractures may show malunion.
Acroosteolysis - resorption of distal phalangeal tufts is the key distinguishing feature. Short metacarpals and phalanges. Sclerosis of all bones. Ungual tufts appear eroded or absent.
Imaging Comparison
- Pyknodysostosis
- Diffuse osteosclerosis
- Osteopetrosis
- Diffuse osteosclerosis
- Pyknodysostosis
- PRESENT (pathognomonic)
- Osteopetrosis
- ABSENT
- Pyknodysostosis
- Persistently open
- Osteopetrosis
- Normal closure
- Pyknodysostosis
- Relatively preserved
- Osteopetrosis
- Erlenmeyer flask deformity
- Pyknodysostosis
- Uniform sclerosis
- Osteopetrosis
- Sandwich or rugger-jersey spine
- Pyknodysostosis
- Absent
- Osteopetrosis
- May be present
Additional Imaging
- Better delineation of skull base abnormalities
- Assessment of paranasal sinus absence
- Evaluation of fracture healing
- Surgical planning when required
- Bone marrow signal may be abnormal
- Assess for cord compression if spinal abnormalities
- Evaluate fracture complications
- Generally not required for diagnosis
Management
Fracture Prevention
Key Principles of Management:
- There is NO disease-modifying treatment for pyknodysostosis
- Bisphosphonates are CONTRAINDICATED - bone resorption is already impaired
- Management is supportive: fracture prevention and treatment
- Dental care is critical to prevent mandibular osteomyelitis
- Genetic counseling for affected families
- Activity modification: Avoid high-impact activities
- Environmental safety: Fall prevention strategies
- Assistive devices: Consider as needed
- Physical therapy: Maintain strength and balance
- Education: Patient and family awareness
- Calcium and Vitamin D: Ensure adequacy
- Weight management: Avoid obesity
- Avoid smoking: Standard bone health advice
- Regular monitoring: Track growth and development
- NO bisphosphonates: Contraindicated
Fracture Management
Acute Fracture Management
- Standard fracture reduction and immobilization
- Expect delayed healing - immobilize longer than usual
- Fixation may be used but bone is brittle
- Avoid multiple drill holes (stress risers in sclerotic bone)
- Sclerotic bone is difficult to drill and tap
- Use sharp instruments; dull bits generate heat
- Pre-drilling may help
- Locking plates may be preferred for better purchase
- Consider augmentation with bone cement in selected cases
- Delayed union is the rule, not the exception
- Patience is required - avoid early hardware removal
- Union may take 2-3 times longer than normal
- Serial radiographs to monitor healing
Standard fracture care principles apply with adaptations for the unique bone characteristics of pyknodysostosis.
Surgical Technique Considerations
- Use sharp, new drill bits
- Low speed, high torque settings
- Irrigation to prevent thermal necrosis
- Pilot holes before larger instruments
- Expect slow progress through dense bone
- Plates and screws may be challenging
- Locking constructs may provide better purchase
- Intramedullary devices possible but difficult to insert
- External fixation an option for complex fractures
Complications and Prognosis
- Recurrent low-energy fractures - lower limb (femur, tibia) most common
- Delayed union / nonunion - the rule rather than the exception (nonunion in roughly a quarter to a third of operated cases)
- Refracture - pooled data: ~25% overall; lowest with intramedullary fixation, highest with external fixation
- Malunion and deformity - from repeated fractures; genu/ankle valgus reported
- Mandibular osteomyelitis / osteonecrosis - characteristic, often post-extraction or after a mandibular fracture
- Dental disease - caries, crowding, delayed eruption, retained deciduous teeth
- Obstructive sleep apnoea - from craniofacial morphology and midface hypoplasia
- Serous otitis media - reported; may need ventilation tubes
Prognosis: Life expectancy is normal and intelligence is unaffected. Morbidity is driven by the fracture burden, slow healing, and jaw complications. With careful fracture management and preventive dental care, most patients achieve good long-term function, though short stature persists and repeated orthopaedic intervention is common.
JAWSComplications and Concerns
Hook:Watch the JAWS - the mandible is especially vulnerable in pyknodysostosis!
Differential Diagnosis: Sclerosing Bone Dysplasias
- Gene/Mechanism
- CTSK (cathepsin K)
- Key Features
- Short stature, open fontanelles, fractures
- Distinguishing Point
- Acroosteolysis present
- Gene/Mechanism
- TCIRG1, CLCN7, others
- Key Features
- Dense bones, Erlenmeyer flask, bone marrow failure (severe)
- Distinguishing Point
- NO acroosteolysis, may have anemia
- Gene/Mechanism
- MAP2K1 somatic
- Key Features
- Dripping candle wax appearance
- Distinguishing Point
- Unilateral, sclerotomal distribution
- Gene/Mechanism
- LEMD3
- Key Features
- Multiple round sclerotic foci
- Distinguishing Point
- Spotted bones, asymptomatic
The key to differentiating pyknodysostosis from osteopetrosis is the presence of acroosteolysis and open fontanelles in pyknodysostosis, both of which are absent in osteopetrosis.
Guidelines, Registries & Global Practice
Global Epidemiology
Pyknodysostosis is an ultra-rare autosomal recessive sclerosing bone dysplasia with an estimated incidence of approximately 1 per 1.7 million live births and fewer than a few hundred reported cases worldwide. Prevalence is higher in populations and regions with frequent consanguineous union (parts of the Middle East, North Africa and South Asia), where homozygosity for pathogenic CTSK variants is more likely. There is no published disease-specific registry; evidence derives from case reports, small institutional series and the pooled systematic review by Taka et al. (2022). Because most surgeons will see at most one case in a career, recognition and referral to a skeletal-dysplasia centre matter more than any single-country pathway.
Why No Society "Guideline" Exists — and What Governs Practice
No orthopaedic society (AAOS, BOA, EFORT, SICOT) or genetics body publishes a condition-specific guideline for pyknodysostosis given its rarity. Practice is therefore extrapolated from generic principles applied to a uniquely sclerotic, brittle bone:
- Governing principle
- Load-sharing/intramedullary constructs preferred where feasible; expect technically hard drilling and delayed union
- Source of guidance
- AO Foundation fracture-management principles; pooled review (Taka 2022)
- Governing principle
- Bisphosphonates and denosumab NOT indicated — resorption is already deficient
- Source of guidance
- Pathophysiology; consensus across reviews
- Governing principle
- Caries prevention and avoidance of extraction to reduce jaw osteomyelitis/osteonecrosis
- Source of guidance
- Oral/maxillofacial literature (Moroni 2023)
- Governing principle
- CTSK molecular confirmation; multidisciplinary skeletal-dysplasia assessment
- Source of guidance
- Clinical genetics standards
- Governing principle
- Recombinant growth hormone has been used in selected children with variable response
- Source of guidance
- Case series (Rovira Martí 2016)
Registry and Evidence Notes
- Implant/arthroplasty registries (NJR, AJRR, AOANJRR, SHAR, Norwegian, NZJR) do not capture pyknodysostosis separately; there are no registry-level implant-survival data for this condition.
- Best available synthesis: the Cureus systematic review (40 patients) shows intramedullary fixation had the lowest refracture rate and external fixation the highest — the closest thing to evidence-based fixation guidance.
High- vs Limited-Resource Practice Variation
- Well-resourced settings: CTSK sequencing, multidisciplinary skeletal-dysplasia and OMFS clinics, growth-hormone access, and image-guided fixation with specialist instruments for sclerotic bone.
- Limited-resource settings: diagnosis is clinical/radiographic (osteosclerosis + acroosteolysis + open fontanelles); fixation relies on available implants, and consanguinity-related caseloads may be relatively higher. Prevention of jaw osteomyelitis through basic dental hygiene is high-value and low-cost everywhere.
Genetic Counselling (Universal)
- Autosomal recessive: unaffected carrier parents face a 25% recurrence risk per pregnancy.
- Offer carrier testing to relatives and discuss consanguinity where relevant.
- Prenatal or preimplantation genetic testing is feasible once the family's CTSK variant(s) are known.
Controversies and Areas of Uncertainty
With fewer than a few hundred reported cases and no randomised data, almost all management is extrapolated. Examiners reward a candidate who states the principle, then frankly acknowledges the uncertainty.
Pooled data suggest intramedullary fixation has the lowest refracture rate and external fixation the highest, but numbers are tiny and selection-biased. Sclerotic bone makes nail insertion technically hard, so plates remain widely used despite a higher refracture signal. No construct is proven superior.
Recombinant growth hormone has been used for short stature with variable, inconsistent response. Some children show GH/IGF-1 axis abnormalities, but predictable height benefit is unproven and it is not standard of care.
The contraindication to bisphosphonates/denosumab is mechanistic, not trial-proven — there are no studies showing harm, only the strong rationale that further suppressing resorption is illogical when resorption is already deficient. Examiners expect you to argue from mechanism.
Cathepsin K inhibitors (e.g. odanacatib) were developed for osteoporosis, not pyknodysostosis, and odanacatib was withdrawn over cardiovascular/stroke safety. There is no disease-modifying drug for pyknodysostosis; gene/enzyme-replacement approaches remain experimental.
The Difficult Airway and Anaesthetic Concerns
The topic lists micrognathia, an obtuse mandibular angle, a high-arched palate, midface hypoplasia, obstructive sleep apnoea and fragile bone, but never assembles the anaesthetic concern - important because these patients need repeated general anaesthetics for their fractures.
- A predictably difficult airway. Micrognathia/retrognathia, the obtuse mandibular angle, a high-arched or grooved palate, midface hypoplasia and a short, stiff neck combine to make laryngoscopy and intubation difficult - plan for it (videolaryngoscopy or an awake/fibreoptic approach; the generic difficult-airway drill is in the general-anaesthesia topic).
- Fragile bone during airway manipulation. The brittle, sclerotic mandible (and cervical spine) can fracture during forceful laryngoscopy or positioning, and teeth are easily damaged - handle gently.
- Obstructive sleep apnoea and respiratory risk. The craniofacial morphology causes obstructive sleep apnoea, so these patients are sensitive to sedatives and opioids and need careful postoperative respiratory monitoring.
Q: What are the key anaesthetic/airway concerns in pyknodysostosis?
A: A predictably difficult airway - micrognathia/retrognathia + obtuse mandibular angle + high-arched/grooved palate + midface hypoplasia + short stiff neck give hard laryngoscopy/intubation (plan videolaryngoscopy or awake fibreoptic); the fragile sclerotic mandible (and cervical spine) can fracture during forceful laryngoscopy or positioning and teeth are easily damaged (gentle handling); and obstructive sleep apnoea from the craniofacial morphology gives sensitivity to sedatives/opioids and needs careful postoperative respiratory monitoring. It matters because these patients need repeated general anaesthetics for their frequent fractures.
Cathepsin K as a Drug Target: the Experiment of Nature
The molecular cards and controversies mention cathepsin K inhibitors but never explain why the enzyme is a drug target or how the inhibitors differ from bisphosphonates.
- The 'experiment of nature'. By showing that losing cathepsin K blocks bone resorption, pyknodysostosis (and its knockout-mouse model) validated cathepsin K as a drug target for diseases of excess resorption - osteoporosis, bone metastasis and myeloma.
- A different kind of antiresorptive. A cathepsin K inhibitor blocks the osteoclast's collagenase without killing the cell, so it reduces resorption while relatively preserving bone formation (the osteoclast still signals to osteoblasts) - an 'uncoupling' advantage over bisphosphonates and denosumab, which suppress both.
- Why it did not reach the clinic. The lead inhibitor odanacatib reduced fractures in trials but was withdrawn (2016) after an increased stroke signal (plus atypical femoral fractures and skin changes from off-target effects). For pyknodysostosis itself - the mirror image, with too little cathepsin K - there is still no cure; enzyme- and gene-replacement approaches remain experimental.
Q: Why is cathepsin K a drug target, and how do its inhibitors differ from bisphosphonates?
A: Pyknodysostosis (plus the knockout mouse) is the experiment of nature proving cathepsin K is the osteoclast collagenase - validating it as a target for diseases of excess resorption (osteoporosis, bone metastasis, myeloma). A cathepsin K inhibitor blocks the collagenase without killing the osteoclast, so it reduces resorption while relatively preserving bone formation (uncoupling) - unlike bisphosphonates/denosumab, which suppress both. The lead drug odanacatib cut fractures but was withdrawn (2016) for an increased stroke risk. For pyknodysostosis itself there is still no cure (enzyme/gene replacement experimental).
Viva Practice Scenarios
Practise clinical reasoning and management decisions out loud
“A 6-year-old boy presents with a femoral shaft fracture after a minor fall. Radiographs show diffusely sclerotic bones throughout. His parents mention he has a 'soft spot' on his head that never closed. What is your differential diagnosis and how would you investigate?”
“You are asked about the difference between pyknodysostosis and osteopetrosis. Both cause dense bones and fractures. How do you distinguish them clinically and radiographically?”
“A teenager with known pyknodysostosis develops pain and swelling of the jaw after a dental extraction. What complication do you suspect and how would you manage it?”
Definition and Key Facts
Molecular Pathogenesis
Clinical Features
Radiographic Features
Distinguishing from Osteopetrosis
Management
Complications
Exam Pearls
Evidence Base
Molecular Basis of Pyknodysostosis
- Identified CTSK (cathepsin K) gene mutations as cause of pyknodysostosis
- Cathepsin K is essential for osteoclast-mediated bone matrix degradation
- Loss-of-function mutations lead to impaired bone resorption
- Confirmed autosomal recessive inheritance pattern
- Established molecular basis for therapeutic targeting
Pycnodysostosis: Role and Regulation of Cathepsin K in Osteoclast Function
- Comprehensive review of cathepsin K biology and the pycnodysostosis phenotype
- Cathepsin K-deficient osteoclasts demineralise bone but cannot degrade the type I collagen matrix
- Acroosteolysis of distal phalanges, short stature and skull deformities are core features
- Cathepsin K inhibitors proposed for diseases of excess resorption (osteoporosis, bone metastasis, myeloma)
- Understanding cathepsin K regulation is the basis for future targeted therapy
Cathepsin K and Bone Remodeling
- Cathepsin K knockout mice recapitulate human pyknodysostosis
- Osteoclasts present but unable to degrade collagen matrix
- Undigested collagen accumulates in resorption lacunae
- Model useful for therapeutic development
- Confirms essential role in bone resorption
Orthopaedic Treatment of Pycnodysostosis: A Systematic Review
- 29 case reports/series pooled (40 patients); 86% had prior fractures and 48% sustained low-energy or spontaneous fractures
- Femur (60%) and tibia (40%) were the commonest fracture sites; 63% of patients had consanguineous parents
- 84% were managed surgically: plate fixation 48%, intramedullary fixation 21%, Ilizarov external fixation 14%
- Overall refracture rate 25%, lowest with intramedullary fixation (0/6) and highest with external fixation (3/4)
- Sclerotic, brittle bone makes any fixation technically demanding; long-term follow-up is essential
Orthopaedic Disorders of Pycnodysostosis: A Report of Five Clinical Cases
- Five patients; all had typical craniofacial features, terminal phalangeal dysplasia and increased bone density
- Four with short stature were treated with growth hormone; most sustained fractures
- Intramedullary nailing is difficult because of skeletal sclerosis; alternative fixation should be considered
- Nonunion occurred in two of five patients and is common in this population
- Newly described associations included serous otitis media and nonunion in pycnodysostosis
Pathological Mandibular Fracture Complicated by Osteonecrosis in Pycnodysostosis
- Confirmed homozygous CTSK pathogenic variant c.746T-to-A (p.Ile249Asn) on direct sequencing
- Spontaneous pathological mandibular fracture with osteonecrosis at age 52, treated with load-bearing osteosynthesis
- Jaw osteomyelitis/osteonecrosis risk is increased, especially after tooth extraction or mandibular fracture
- Dental abnormalities (delayed eruption, hypodontia, malocclusion, increased caries) are frequent and warrant surveillance
- Recommends considering pycnodysostosis in osteosclerosis even without brachydactyly or short stature